News FDA starts review of Summit's VEGFxPD-1 bispecific Summit moves ahead in the race to bring a VEGFxPD-(L)1 drug to market, after the FDA started a review of ivonescimab in lung cancer.
News Tenpoint eyes presbyopia drug launch after FDA nod Tenpoint is set to join the US market for drugs to treat presbyopia, taking on rival therapies from AbbVie, Orasis, and LENZ with a dual-acting rival.
News Digital musculoskeletal care firm Sword buys rival Kaia US digital physical therapy specialist Sword Health has bought its competitor Kaia Health for $285 million, positioning it for expansion in Europe.
News Otsuka preps for July decision on centanafadine for ADHD The FDA has started a priority review of Otsuka's triple-acting drug for ADHD, setting up a decision on the first-in-class drug in July.
News Halozyme diversifies in drug delivery with Surf Bio buy Halozyme has expanded its portfolio of drug delivery technologies for a second time in a few months with the acquisition of Surf Bio for up to $400m.
News Eikon prices its IPO, seeking to raise $318m Roger Perlmutter's new cancer biotech Eikon has priced its IPO, looking to raise up to $318m and achieve a $900m-plus valuation.
News Trial miss doesn't dent Biogen's faith in Alzheimer's drug Biogen will advance its tau-targeting Alzheimer's disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
